



ERRATA

Erratum 1:

The following erratum pertains to the formula for Ketamine 40-mg/5-mL Flavored Oral Solution that was included within the following article: McNulty JP, Hahn K. Compounded oral ketamine for severe depression, anxiety, and pain in a hospice patient with end-stage chronic obstructive pulmonary disease, cardiopulmonary

failure, and severe renal insufficiency: A case report. *IJPC*. 2012; 16(5): 364–368.

The yield of this formula should have been shown as 135 mL instead of 100 mL.

Erratum 2:

The following erratum pertains to the following article: Stevens JT. Summary of educational offerings provided by compounding support companies in 2019. *IJPC*. 2019; 23(3): 100–103.

The information provided in Table 1 of that article was incomplete, and the following revised Table 1 provides the latest update to that information.

TABLE 1.

2019 EDUCATIONAL OFFERINGS BY COMPOUNDING SUPPORT COMPANIES

EDUCATIONAL OFFERINGS/ TRAINING	COMPOUNDING SUPPORT COMPANIES							
	ACA	FAGRON	FDA	HUMCO	LETCO	MEDISCA	PCCA	SPECTRUM
Consultation Services								
Dermatology								
Comprehensive/Fundamentals/ Refresher								
Hormone Replacement Therapy								
Managing Treatment Side Effects								
Marketing								
Nonsterile (<i>USP</i> <795>)								
Online, On-demand, Self-paced								
Pain Management								
Software Training								
Sterile (<i>USP</i> <797>)								
<i>USP</i> 800								
Veterinary								
Website (Videos, Webinar, Podcasts, etc.)								

= Not associated with CE credit

ACA = American College of Apothecaries; FDA = U.S. Food & Drug Administration; PCCA = Professional Compounding Centers of America; *USP* = *United States Pharmacopeia*
Sources: ACA; Fagron Academy; U.S. Food & Drug Administration; Humco; Letco Medical; MEDISCA; PCCA; Spectrum